ALX Oncology Narrows 2026 Loss Estimate to $0.88, Shares Up 80.5%
Analysts have revised ALX Oncology’s 2026 loss per share estimate from $1.21 to $0.88 over the past 60 days, reflecting improved outlook for its pipeline. Shares have surged 80.5% year to date despite four consecutive quarterly earnings misses averaging a 12.8% negative surprise.
1. Estimate Revision Trends
Over the past 60 days, sell-side analysts have cut ALX Oncology’s 2026 loss per share projection from $1.21 to $0.88, indicating growing confidence in its late-stage or preclinical assets. This downward adjustment suggests that potential clinical milestones and cost efficiencies are reshaping profitability expectations.
2. Year-to-Date Share Performance
ALX Oncology’s stock has climbed 80.5% since January, markedly outperforming industry peers. This rally reflects investor enthusiasm around upcoming readouts and potential partnerships that could de-risk key programs in its oncology pipeline.
3. Earnings Track Record
The company has missed consensus EPS estimates in each of the last four quarters, with an average shortfall of 12.8%. These repeated negatives underscore the importance of achieving clinical successes and regulatory advances to turn around market sentiment.